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Purpose  Experimental studies suggested that green tea may have an anticancer effect on 2 
hematologic neoplasms. However, few prospective studies have been conducted. 3 
Methods  A total of 65,042 individuals aged 40 to 79 years participated in this study and 4 
completed a self-administered questionnaire about their lifestyle and medical history at 5 
baseline (1988–1990). Of these, 52,462 individuals living in 24 communities with 6 
information on incident hematologic neoplasms available in the cancer registry, who did 7 
not have a history of cancer and provided valid information on frequency of green tea 8 
consumption were followed through 2009. Hazard ratios (HRs) and 95% confidence 9 
intervals (CIs) for the incidence of hematologic neoplasms according to green tea 10 
consumption were analyzed. 11 
Results  The incidence of hematologic neoplasms during a median follow-up of 13.3-years 12 
was 323. Compared with the never green tea drinkers, the multivariate HRs and 95% CIs 13 
for total hematologic neoplasms in green tea drinkers of ≤2 cups/day, 3–4 cups/day, and ≥5 14 
cups/day were 0.65 (0.42–1.00), 0.73 (0.47–1.13), and 0.63 (0.42–0.96), respectively. The 15 
association was more prominent for acute myeloid leukemias and follicular lymphomas. 16 
Conclusions  The present cohort study suggests a protective effect of green tea against 17 
hematologic neoplasms, especially acute myeloid leukemias. 18 
 19 
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Experimental studies have suggested that consumption of green tea may prevent various 2 
cancers including hematologic neoplasms[1-3]. Green tea constituents such as 3 
epigallocatechin-3-gallate (EGCG) induce apoptosis in a variety of cancer cells including 4 
human myeloid leukemia cells[4-6]. EGCG induces apoptosis of acute myeloid leukemia 5 
cells by increasing the amount of intracellular reactive oxygen species[6]. However, the 6 
epidemiologic evidence is limited and controversial. A previous Japanese cohort study 7 
showed that a higher frequency of green tea consumption was associated with a lower risk 8 
of hematologic neoplasms[7]. Meanwhile, another Japanese cohort study found no 9 
significant association between green tea consumption and the risk of  acute myeloid 10 
leukemia or myelodysplastic syndromes[8]. Case-control studies conducted in Taiwan[9] 11 
and China[10] reported that high intake of green tea was associated with lower risk of 12 
leukemias such as myeloid leukemia. 13 
The incidence of hematologic neoplasms is known to be relatively high among 14 
whites and to be relatively low among Asians[11]. Ecologically, tea production in 2013 was 15 
1050 g/person in Asia, 120 g/person in the Americas, and 0.4 g/person in Europe[12]. In 16 
this context, we hypothesized that the difference in the incidence of hematologic neoplasms 17 
between white and Asian populations may be partly explained by green tea consumption. 18 
We used data from a population-based cohort study to examine the association between 19 
green tea consumption and risk of mortality from and incidence of hematologic neoplasms 20 





Materials  and Methods 2 
Study population 3 
The Japan Collaborative Cohort (JACC) Study for Evaluation of Cancer Risk is a large 4 
community-based prospective study, started between 1988 and 1990. The details of the 5 
JACC study have been reported elsewhere[13]. In brief, a total of 110,585 individuals 6 
(46,395 men and 64,190 women), aged 40 to 79 years and living in 45 communities across 7 
Japan, participated in the study and completed self-administered questionnaires about their 8 
lifestyles and medical histories of cardiovascular disease and cancer. From these 9 
questionnaires, data on frequency of green tea consumption were available for 33,154 men 10 
and 46,028 women. We excluded 15 persons who answered that their daily green tea 11 
consumption was >20 cups/day and 1461 persons who had a history of cancer at baseline. 12 
Among the remaining 77,706 participants (32,733 men and 44,973 women), we involved 13 
52,462 individuals (21,791 men and 30,671 women) living in 24 communities with 14 
information on incident hematologic neoplasms available in the cancer registry. According 15 
to the guidelines of the Council for International Organizations of Medical Science, written 16 
informed consent to participate in this epidemiologic study was obtained from the 17 
participants or community representatives before they completed the questionnaire [14]. 18 






Assessment of green tea consumption and other variables 1 
The participants were asked to state their average rate of green tea consumption during the 2 
previous year. They could select any of 5 frequency responses: “almost never,” “1–2 3 
cups/month,” “1–2 cups/week,” “3–4 cups/week,” and “almost every day.” Participants 4 
who selected the response “almost every day” were asked to state their average 5 
consumption of green tea in numbers of cups per day. We combined the 4 categories of 6 
consumption (1–2 cups/month, 1–2 cups/week, 3–4 cups/week, and 1–2 cups/day) into the 7 
single category ≤2 cups/day and classified the categories of consumption as never, <2 8 
cups/day, 3–4 cups/day, and ≥5 cups/day. Regarding reproducibility, the Spearman 9 
correlation coefficient between the 2 questionnaires, administered 1 year apart for 85 10 
participants (8 men and 77 women), was 0.79 for green tea[15]. Regarding validity, the 11 
Spearman correlation coefficient between the average of the 2 questionnaires and four 3-12 
day dietary records and four 1-week dietary records was 0.47 (25.4 cups and 30.1 cups per 13 
week) for green tea[15].When we restricted the data to the 77 women, the result was 14 
essentially the same. 15 
In the baseline questionnaire, we also asked lifestyle questions related to age; sex; 16 
height; weight; smoking status; alcohol intake status; frequency of dietary intakes of fish, 17 
vegetable, meat, and bean products; and educational status (age of the highest school 18 
attainment). Body mass index (BMI) was calculated by dividing the self-reported weight in 19 




fish, vegetable, meat, and bean products were evaluated on the basis of the responses 1 
regarding food frequency and converted to a daily amount of intake[15]. 2 
 3 
Follow-up and assessment of hematologic neoplasms 4 
For each participant, person-years of follow-up was calculated from the date of filling out 5 
the baseline questionnaire to diagnosis of a neoplasm, death, moving out of the community, 6 
or the end of 2009, whichever occurred first; exceptions were made for 4 areas in 1999, 4 7 
areas in 2003, and 2 areas in 2008. The median follow-up was 13.3 years (range, 0.01–21.5 8 
years). The diagnosis of neoplasms was based on a systematic review of the records of local 9 
major hospitals and of the population-based cancer registries conducting the follow-up. The 10 
investigators conducted a systematic review of the death certificates, all of which were 11 
forwarded to the public health center in the area of residency. The mortality data were sent 12 
centrally to the Ministry of Health and Welfare, and the underlying causes of death were 13 
coded according to the 10th Revision of the International Statistical Classification of 14 
Diseases and Related Health Problems (ICD10). In Japan, registration of death is legally 15 
required and is believed to be followed across the country. Thus, all of the deaths that 16 
occurred in the cohort were ascertained by death certificates from a public health center, 17 
except for those of participants who died after they had moved from their original 18 
community, in which case the participant was censored. The incidence data were coded 19 
according to the ICD10. We defined hematologic neoplasms as C810–C969 and D460–20 




neoplasms (ICD10 codes C810–C889, C900–C903, C910–C919, C947, and D472); 1 
myeloid neoplasms (ICD10 codes C920–C944, D460–D471, and D473); leukemia of 2 
unspecified cell type (ICD10 codes C950-C959); and other and unspecified malignant 3 
neoplasms of lymphoid, and hematopoietic and related tissue (ICD10 codes C960-C969). 4 
Lymphoid neoplasms were further categorized into Hodgkin lymphomas (C810–C819) and 5 
non-Hodgkin lymphomas (C820–C919, C947, and D472). Non-Hodgkin lymphomas were 6 
further categorized into B cell non-Hodgkin lymphomas (C820–C829, C830–C839, C851, 7 
C852, C857, C880-C884, C900–C903, C911–C914, C918, D472); T/NK cell non-Hodgkin 8 
lymphomas (C840–C849, C860–C866, C915–C917, C947); acute lymphoid leukemias 9 
(C910); and non-Hodgkin lymphomas, not otherwise specified (C859, C919). B cell non-10 
Hodgkin lymphoma were further categorized into follicular lymphomas (C820–C829); 11 
diffuse large B cell lymphomas (C833); plasma cell neoplasms (C900–C903); and chronic 12 
lymphocytic leukemia/small lymphocytic lymphomas (C911, C830). Myeloid neoplasms 13 
were further categorized into acute myeloid leukemias (C920, C924–C926, C928, C930, 14 
C940, and C942); chronic myeloid leukemias (C921, C922, and C931); monocytic 15 
leukemias, unspecified (C939); myelodysplastic syndromes (D460–D469); and chronic 16 
myeloproliferative diseases (D471). 17 
 18 
Statistical analysis 19 
The age-adjusted means and proportions of potential confounding variables were calculated 20 




categories was tested by analysis of covariance. Age- and sex-adjusted and area-stratified 1 
hazard ratios (HRs) and 95% confidence intervals (CIs) for hematologic neoplasms were 2 
calculated in each category of green tea consumption and compared with the never-drinker 3 
group by use of the Cox proportional hazards model. In addition, categories of drinkers of 4 
≥1 cup/month of green tea (ie, ≤2cups/day, 3–4 cups/day, and ≥5 cups/day) were pooled 5 
into the single category (any drinker), and the HRs and 95% CIs for hematologic neoplasms 6 
were calculated. For multivariate analyses, we included the following factors in the models: 7 
age (years); sex; smoking status (never, former, and current of 1–19 or ≥20 cigarettes/day); 8 
body mass index (<18.5, 18.5–20.0, 20.0–23.0, 23.0–25.0, and ≥25.0 kg/m2); alcohol intake 9 
status (never, former, and current <23, 23–<46, 46–<69, and ≥69 g ethanol/day based on 10 
the Japanese traditional volume); fish intake as quintiles of the sum of consumption 11 
frequencies of raw fish, boiled fish paste, and dried fish (<22.1, 22.4–35.2, 35.2–48.0, 12 
48.2–71.7, ≥72.0 g/day); vegetable intake as quintiles of the sum of consumption 13 
frequencies of spinach, carrots, tomatoes, cabbage, Chinese cabbage, and edible wild plants 14 
(<51.8, 51.9–80.1, 80.1–102.0, 102.1–139.1, ≥139.1 g/day); meat intake as quintiles of the 15 
sum of consumption frequencies of beef, pork, processed meat, chicken, and liver (<14.2, 16 
14.3–23.5, 23.5–30.4, 30.4–41.9, ≥42.0 g/day); bean product intake as quintiles of the sum 17 
of consumption frequencies of boiled beans and soybean curd (<14.8, 20.0–30.0, 32.0–32.8, 18 
38.6–60.0, ≥62.0 g/day); energy intake (<1171, 1172–1378, 1378–1574, 1574–1859, ≥1859 19 
kcal/day); and educational status (education until 18 or ≥19 years of age). Missing data 20 
were allocated to another category for each covariate. The linear trend of HRs across the 21 




cups/month” to 0.05, “1–2 cups/week” to 0.214, “3–4 cups/week” to 0.5, and “almost every 1 
day” to the number of cups of green tea consumed/day, was tested using the Cox 2 
proportional hazards model. To exclude the impact of reverse causation, we also performed 3 
the analyses excluding cases occurring 5 and 10 years from baseline. We also performed the 4 
analyses excluding death certificate-only cases. The proportional hazards assumption was 5 
tested using time by grean tea consumption interaction terms and was not violated for each 6 
outcome. All analyses were conducted using the SAS statistical package, version 9.4. The P 7 
values for the statistical tests were 2-tailed, and values <0.05 were considered significant. 8 
 9 
Code availability 10 
The computer code used to generate results that were central to this paper’s conclusions is 11 
available from the corresponding author. 12 
 13 
Results 14 
Participant characteristics 15 
The baseline characteristics of the study cohort according to green tea consumption are 16 
shown in Table 1. Both men and women with higher green tea consumption were older than 17 
those who did not drink it. As green tea consumption increased, the proportion of current 18 
smokers was higher in men but lower in women. The proportions of current alcohol drinker 19 




or women. Higher educational attainment was associated with higher consumption of green 1 
tea in both men and women. The mean consumptions of fish, vegetables, meat, beans, and 2 
energy intake were positively associated with green tea consumption in both men and 3 
women. 4 
 5 
Green tea consumption and incidence of hematologic neoplasms 6 
In the 52,462 participants, during a median follow-up of 13.3 years, there were 323 incident 7 
hematologic neoplasms: 219 lymphoid neoplasms (8 Hodgkin lymphomas, 211 non-8 
Hodgkin lymphomas); 95 myeloid neoplasms (48 acute myeloid leukemias, 10 chronic 9 
myeloid leukemias, 1 monocytic leukemia, unspecified, 34 myelodysplastic syndromes, 10 
and 2 chronic myeloproliferative diseases); 6 leukemias of unspecified cell type; and 3 11 
other and unspecified malignant neoplasms of lymphoid and hematopoietic and related 12 
tissue. Among the non-Hodgkin lynphomas, there were 108 B cell non-Hodgkin 13 
lymphomas; 10 T/NK cell non-Hodgkin lymphomas; 5 acute lymphoid leukemias; and 88 14 
non-Hodgkin lymphomas, not otherwise specified. B cell non-Hodgkin lymphomas 15 
included 10 follicular lymphomas, 16 diffuse large B cell lymphomas, 67 plasma cell 16 
neoplasms, 6 chronic lympocytic leukemia/small lymphocytic lymphomas, and 9 other B 17 
cell non-Hodgkin lymphomas. The frequency of green tea consumption was nonlinearly 18 
and inversely associated with risk of total hematologic neoplasms (Table 2). The 19 
multivariate HR (95% CI) of all hematologic neoplasms was 0.63 (0.42–0.96) for persons 20 




tea drinkers versus never drinkers was 0.66 (0.45–0.98). Such an association was prominent 1 
for acute myeloid leukemias and follicular lymphomas. As for acute myeloid leukemias, 2 
follicular lymphomas, and chronic lympocytic leukemia/small lymphocytic lymphomas, the 3 
risks were lower in any drinkers. No such association was found for plasma cell neoplasms. 4 
Similar results were observed after the exclusion of cases that occurred 5 and 10 years from 5 
baseline: the multivariate HRs for incident total hematologic neoplasms and acute myeloid 6 
leukemias for persons who drank ≥5 cups/day of green tea compared with never drinkers 7 
were 0.51 (0.31–0.84) and 0.31 (0.11–0.89), respectively, when early 5-year incidence was 8 
excluded, and  0.51 (0.28–0.94) and 0.37 (0.09–1.47), respectively, when early 10-year 9 
incidence was excluded. Similar results were observed after the exclusion of death 10 
certificate-only cases; the multivariate HRs for incident total hematologic neoplasms and 11 
acute myeloid leukemias for persons who drank ≥5 cups/day green tea as compared with 12 
never drinkers were 0.64 (0.41–1.01) and 0.36 (0.14–0.95), respectively. We could not 13 
evaluate follicular lymphomas in the same manner because of the small numbers of cases. 14 
 15 
Discussion 16 
In this large prospective study of Japanese men and women, the frequency of green tea 17 
consumption was inversely associated with the incidence of hematologic neoplasms, more 18 
specifically, with the incidence of acute myeloid leukemias and follicular lymphomas. The 19 
exclusion of cases that occurred within 5 and 10 years from baseline did not largely alter 20 




Our results extend the evidence obtained from several previous studies of Asian 1 
populations. Two case-control studies from China and Taiwan showed significant inverse 2 
associations between green tea consumption and leukemia[9, 10]. A previous cohort study 3 
of 51,253 Japanese (Ohsaki Study) showed that persons who drank ≥5 cups of green tea a 4 
day had a lower risk of incident hematologic neoplasms (HR and 95% CI: 0.58, 0.37–0.89) 5 
when compared with those who drank <1 cup/day, with a threshold of 5 cups/day after 6 
adjustment for age, sex, educational level, cigarette smoking, alcohol consumption, fish 7 
consumption, and soybean products consumption [7]. In that study, the inverse association 8 
was observed mainly for lymphoid neoplasms, not for myeloid neoplasms, although the 9 
neoplasms were not classified into preciser subtypes. Another cohort study of 95,807 10 
Japanese (JPHC Study) with 85 incident acute myeloid leukemias and 70 incident 11 
myelodysplastic syndromes did not find any associations between green tea consumption 12 
and any of the outcomes. [8]. Unlike our study, neither the Ohsaki Study [7] nor the JPHC 13 
Study [8] distinguished never green tea drinkers from the <1 cup/day category, and this, as 14 
well as the lower statistical power, may be a major reason why those studies did not detect 15 
an association between green tea consumption and risk of acute myeloid leukemias. 16 
We consider that the anticancer effects of EGCG, a component of green tea, could explain 17 
our results, although there is poor evidence for the bioavailability of EGCG with <1 18 
cup/day of green tea consumption. A possible mechanism could be that EGCG induces 19 
apoptosis of cancer cells. Nakazato et al showed that EGCG induced apoptosis in retinoic 20 
acid-resistant acute promyelocytic leukemia and acute myeloid leukemia and that reactive 21 




cells[6]. Notably, the apoptosis was observed in myeloperoxidase-positive leukemic cells, 1 
ie, myeloid leukemia cells, but not in myeloperoxidase-negative leukemic cells[16]. 2 
Another possible mechanism could be that EGCG inhibits cancer cell proliferation through 3 
a cell-surface receptor. Tachibana et al showed that the growth of cells transfected with the 4 
67-kDa laminin receptor was inhibited when the cells were treated with 0.1 μmol/L 5 
(equivalent to 2–3 cups of tea[17]) or 1.0 μmol/L (equivalent to 7–9 cups of tea[17]) 6 
EGCG[18]. This growth-suppressive effect was completely eliminated when the cells were 7 
treated with anti-67-kDa laminin receptor antibody before the addition of EGCG[17]. 8 
Montuori et al reported that 42% of acute myeloid leukemia patients had enhanced 9 
expression of the 67-kDa laminin receptor[19]. These lines of biological evidence support 10 
our results and may explain the mechanisms of the observed association between green tea 11 
and hematologic malignancies, especially acute myeloid leukemias. 12 
Our study has several limitations. First, we did not have enough information related to 13 
occupational exposures, such as ionizing radiation and benzene, which may affect the risk 14 
of hematologic neoplasms[20]. We believe that the impact of these exposures should not be 15 
very large at the population level. To minimize this impact, we adjusted for potential 16 
confounders in the statistical models, but the residual confounding by unmeasured variables 17 
should still be considered. Second, we did not have information on several risk factors for 18 
hematologic neoplasms, such as family history of hematologic neoplasms, past history of 19 
infection, immunologic disorders and chemotherapy, although these may be less likely to 20 
be correlated with green tea consumption. Third, there might be a measurement error 21 




questionnaires was validated by a previous study [15]. Fourth, we only have single 1 
measurements of dietary and lifestyle habits, which may change over time. Fifth, 2 
confounding by dietary components other than green tea should be considered, although we 3 
minimized this confounding by adjusting for as many dietary factors as possible. Sixth, our 4 
assessment of hematologic neoplasms was based on hospital records and death ICD codes. 5 
Although there is no direct evidence of the validity of ICD codes for hematologic 6 
neoplasms, the codes seem quite specific, but probably not sensitive enough to capture 7 
hematologic neoplasms. Thus, the approach used in the current study might have led to an 8 
underestimation of hematologic neoplasm events. Seventh, the quality of the cancer registry 9 
in the present study was not high enough in terms of hematologic neoplasms: the 10 
proportions of death certificate-only incident cases among all hematologic neoplasms and 11 
acute myeloid leukemias were 15% and 4%, respectively. However, the results obtained 12 
after the exclusion of the death certificate-only incident cases did not largely alter the 13 
overall results. Moreover, the accuracy of our cancer registry is the highest when compared 14 
with those of previous reports [7, 8]. Eighth, the number of cases of hematologic neoplasms 15 
in this cohort was modest. However, this is the largest prospective study that has reported 16 
an association between green tea and hematologic neoplasms. 17 
In conclusion, the present cohort study suggests a protective effect of green tea against 18 




Appendix: Study group membership list 
Current members of the JACC Study Group include: Dr. Akiko Tamakoshi (present 
chairperson of the study group), Hokkaido University Graduate School of Medicine; Dr. 
Mitsuru Mori, Sapporo Medical University School of Medicine; Dr. Yoshihiro Kaneko, 
Akita University Graduate School of Medicine; Dr. Ichiro Tsuji, Tohoku University 
Graduate School of Medicine; Dr. Yosikazu Nakamura, Jichi Medical School; Dr. Hiroyasu 
Iso, Osaka University School of Medicine; Dr. Kazumasa Yamagishi, Faculty of Medicine, 
University of Tsukuba; Dr. Haruo Mikami, Chiba Cancer Center; Dr. Michiko Kurosawa, 
Juntendo University School of Medicine; Dr. Yoshiharu Hoshiyama, Yokohama Soei 
University; Dr. Naohito Tanabe, University of Niigata Prefecture; Dr. Koji Tamakoshi, 
Nagoya University Graduate School of Health Science; Dr. Kenji Wakai, Nagoya 
University Graduate School of Medicine; Dr. Shinkan Tokudome, National Institute of 
Health and Nutrition; Dr. Koji Suzuki, Fujita Health University School of Health Sciences; 
Drs. Shuji Hashimoto and Hiroshi Yatsuya, Fujita Health University School of Medicine; 
Dr. Shogo Kikuchi, Aichi Medical University School of Medicine; Dr. Yasuhiko Wada, 
Faculty of Nutrition, University of Kochi; Dr. Takashi Kawamura, Kyoto University Health 
Service; Dr. Yoshiyuki Watanabe, Kyoto Prefectural University of Medicine Graduate 
School of Medical Science; Dr. Kotaro Ozasa, Radiation Effects Research Foundation; Dr. 
Tsuneharu Miki, Kyoto Prefectural University of Medicine Graduate School of Medical 
Science; Dr. Chigusa Date, School of Human Science and Environment, University of 
Hyogo; Dr. Kiyomi Sakata, Iwate Medical University; Dr. Yoichi Kurozawa, Tottori 




University of Occupational and Environmental Health; Dr. Akira Shibata, Kurume 
University; Dr. Naoyuki Okamoto, Kanagawa Cancer Center; and Dr. Hideo Shio, Long-
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Never ≤2cups/day 3-4cups/day ≥5cups/day P Value
Men, n 1539 5552 5189 9511
Age at baseline, years 57.4 55.7 57.6 58.5 <.0001
Current smokers, % 49.4 52.7 50.4 54.1 <.0001
Current drinkers, % 70.2 76.0 76.8 74.5 <.0001
Body mass index, kg/m2 22.6 22.6 22.6 22.6 <.0001
College or higher education, % 17.0 21.5 21.1 19.3 .001
Fish intake, g/day 41.8 45.9 45.4 48.9 <.0001
Vegetable intake, g/day 82.6 87.7 89.0 94.4 <.0001
Meat intake, g/day 27.0 29.0 28.9 30.0 <.0001
Bean product intake, g/day 33.8 35.3 35.7 36.8 <.0001
Energy intake, kcal/day 1596 1657 1668 1783 <.0001
Women, n 2620 7344 7923 12784
Age at baseline, years 57.5 56.3 56.3 58.6 <.0001
Current smokers, % 6.6 6.1 4.3 5.2 <.0001
Current drinkers, % 21.6 26.7 25.2 23.3 <.0001
Body mass index, kg/m2 22.8 22.8 22.6 22.8 <.0001
College or higher education, % 9.5 11.1 11.8 10.9 <.0001
Fish intake, g/day 43.4 45.2 46.2 49.7 <.0001
Vegetable intake, g/day 96.2 99.1 102.2 106.2 <.0001
Meat intake, g/day 27.7 29.5 30.6 31.3 <.0001
Bean product intake, g/day 37.8 39.8 40.1 41.8 <.0001
Energy intake, kcal/day 1313 1359 1394 1447 <.0001
Green tea consumption, cups/day





Never ≤2cups/day 3-4cups/day ≥5cups/day P  Value for Trend Any drinker2
50,853 166,358 158,215 294,250 618,823
Number of persons 4,159 12,896 13112 22,295 48,303
  No. of cases 31 69 78 145 292
1.0 0.65 (0.42-0.99) 0.73 (0.47-1.13) 0.63 (0.42-0.96) 0.63 0.66 (0.45-0.98)
1.0 0.65 (0.42-1.00) 0.73 (0.47-1.13) 0.63 (0.42-0.96) 0.64 0.66 (0.45-0.98)
  No. of cases 19 49 56 95 200
1.0 0.78 (0.46-1.34) 0.86 (0.50-1.48) 0.69 (0.41-1.16) 0.69 0.76 (0.47-1.25)
1.0 0.79 (0.46-1.35) 0.86 (0.50-1.49) 0.70 (0.41-1.19) 0.77 0.77 (0.47-1.27)
  No. of cases 0 3 2 3 8
- - - - - -
- - - - - -
  No. of cases 19 46 54 92 192
1.0 0.74 (0.43-1.28) 0.85 (0.49-1.46) 0.68 (0.40-1.16) 0.78 0.75 (0.46-1.22)
1.0 0.75 (0.44-1.30) 0.85 (0.49-1.47) 0.70 (0.41-1.19) 0.86 0.76 (0.46-1.24)
  No. of cases 10 27 25 46 98
1.0 0.76 (0.36-1.58) 0.69 (0.32-1.48) 0.59 (0.29-1.23) 0.52 0.68 (0.34-1.34)
1.0 0.74 (0.35-1.54) 0.66 (0.31-1.42) 0.58 (0.28-1.20) 0.51 0.65 (0.33-1.30)
  No. of cases 1 1 3 5 9
1.0 0.32 (0.02-5.18) 0.97 (0.10-9.71) 0.73 (0.08-6.72) 0.61 0.66 (0.08-5.45)
1.0 0.24 (0.01-4.86) 1.12 (0.09-13.32) 0.90 (0.08-9.87) 0.91 0.70 (0.08-6.62)
  No. of cases 8 17 25 38 80
1.0 0.72 (0.31-1.69) 0.96 (0.42-2.20) 0.71 (0.32-1.60) 0.84 0.78 (0.37-1.67)
1.0 0.76 (0.32-1.79) 1.01 (0.44-2.32) 0.76 (0.34-1.73) 0.72 0.83 (0.39-1.78)
  No. of cases 0 1 1 3 5
- - - - - -
- - - - - -
  No. of cases 2 2 2 4 8
1.0 0.19 (0.03-1.38) 0.22 (0.03-1.71) 0.19 (0.03-1.21) 0.69 0.20 (0.04-1.01)
1.0 0.16 (0.02-1.27) 0.15 (0.02-1.32) 0.14 (0.02-0.99) 0.71 0.15 (0.03-0.88)
  No. of cases 2 4 4 6 14
1.0 0.53 (0.10-2.98) 0.62 (0.11-3.59) 0.47 (0.09-2.49) 0.90 0.53 (0.12-2.41)
1.0 0.53 (0.09-3.09) 0.71 (0.12-4.27) 0.49 (0.09-2.71) 0.91 0.55 (0.12-2.62)
  No. of cases 4 19 15 29 63
1.0 1.47 (0.49-4.39) 1.12 (0.36-3.50) 1.03 (0.34-3.10) 0.39 1.22 (0.43-3.48)
1.0 1.36 (0.46-4.08) 1.03 (0.33-3.22) 0.95 (0.31-2.87) 0.33 1.13 (0.39-3.22)
  No. of cases 2 0 0 4 4
1.0 - - - - 0.12 (0.02-0.81)
1.0 - - - - 0.09 (0.01-0.96)
  No. of cases 10 19 20 46 85
1.0 0.50 (0.23-1.08) 0.58 (0.26-1.30) 0.59 (0.28-1.25) 0.91 0.55 (0.27-1.10)
1.0 0.49 (0.23-1.08) 0.58 (0.26-1.30) 0.58 (0.27-1.24) 0.83 0.54 (0.27-1.10)
  No. of cases 7 9 10 22 41
1.0 0.32 (0.12-0.89) 0.35 (0.13-0.98) 0.35 (0.14-0.90) 0.41 0.34 (0.15-0.81)
1.0 0.33 (0.12-0.92) 0.37 (0.13-1.04) 0.35 (0.14-0.92) 0.36 0.35 (0.15-0.84)
  No. of cases 0 2 3 5 10
- - - - - -
- - - - - -
  No. of cases 3 8 6 17 31
1.0 0.75 (0.20-2.87) 0.69 (0.16-2.99) 0.86 (0.23-3.28) 0.89 0.78 (0.22-2.68)
1.0 0.69 (0.18-2.68) 0.63 (0.15-2.75) 0.81 (0.21-3.14) 0.86 0.72 (0.21-2.50)
  Multivariate1 HR (95%CI)
  Multivariate1 HR (95%CI)
Diffuse large B cell lymphomas
  Age- and sex- adjusted, area- stratified HR (95%CI)
B cell non-Hodgkin lymphomas
  Age- and sex- adjusted, area- stratified HR (95%CI)
  Multivariate1 HR (95%CI)
Follicular lymphomas
  Age- and sex- adjusted, area- stratified HR (95%CI)
Acute lymphoid leukemias
  Age- and sex- adjusted, area- stratified HR (95%CI)
  Multivariate1 HR (95%CI)
Chronic lympocytic leukemia/small lymphocytic lymphomas
1Multivariate model included age, sex, education level, cigarette smoking, alcohol intake, body mass index, fish intake, vegetable intake, meat intake, bean products intake, bean products intake, and energy intake .
Myelodysplastic syndromes
  Age- and sex- adjusted, area- stratified HR (95%CI)
  Multivariate1 HR (95%CI)
  Age- and sex- adjusted, area- stratified HR (95%CI)
  Multivariate1 HR (95%CI)
  Multivariate1 HR (95%CI)
  Age- and sex- adjusted, area- stratified HR (95%CI)
  Multivariate1 HR (95%CI)
Non-Hodgkin lymphomas, NOS
  Age- and sex- adjusted, area- stratified HR (95%CI)
  Multivariate1 HR (95%CI)
  Age- and sex- adjusted, area- stratified HR (95%CI)
Hodgkin lymphomas
2Categories of green tea consumers of ≥1 cup/month of green tea (i.e. 1cup/month-2cups/day,  3-4 cups/day, and ≥5 cups/day)
  Multivariate1 HR (95%CI)
Plasma cell neoplasms
  Age- and sex- adjusted, area- stratified HR (95%CI)
  Multivariate1 HR (95%CI)
Myeloid neoplasms
  Age- and sex- adjusted, area- stratified HR (95%CI)
  Multivariate1 HR (95%CI)
Acute myeloid leukemias
  Age- and sex- adjusted, area- stratified HR (95%CI)
Chronic myeloid leukemias
  Age- and sex- adjusted, area- stratified HR (95%CI)
  Multivariate1 HR (95%CI)
T/NK cell non-Hodgkin lymphomas
Table 2. Age- and sex- adjusted and area-stratified multivariate hazard ratios and 95% confidence intervals of incidence of hematologic malignancies according to green tea consumption.
Lymphoid neoplasms
  Age- and sex- adjusted, area- stratified HR (95%CI)
  Multivariate1 HR (95%CI)
Non-Hodgkin lymphomas
  Age- and sex- adjusted, area- stratified HR (95%CI)
  Multivariate1 HR (95%CI)
  Multivariate1 HR (95%CI)
Green tea consumption, cups/day
Person-years
Total hematologic neoplasms
  Age- and sex- adjusted, area- stratified HR (95%CI)
 
